Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CAMP4 Therapeutics Corporation (CAMP : NSDQ)

• Company Description    CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based in CAMBRIDGE, Mass. Number of Employees: 48

• Price / Volume Information    Yesterday's Closing Price: $4.41 Daily Weekly Monthly 20 Day Moving Average: 303,752 shares Shares Outstanding: 62.75 (millions) Market Capitalization: $276.74 (millions) Beta: 0.27 52 Week High: $7.75 52 Week Low: $1.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.50% 4.97% 12 Week 11.36% 8.99% Year To Date -28.06% -36.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 TALCOTT AVENUE SUITE 201 - WATERTOWN,MA 02472 USA ph: 617-651-8867 fax: - ir@camp4tx.com http://www.camp4tx.com

• General Corporate Information    Officers Josh Mandel-Brehm - President; Chief Executive Officer and Director Douglas Williams - Chairman of the Board Kelly Gold - Chief Financial Officer Michael Higgins - Director Steven Holtzman - Director Peer Information CAMP4 Therapeutics Corporation (CORR.) CAMP4 Therapeutics Corporation (RSPI) CAMP4 Therapeutics Corporation (CGXP) CAMP4 Therapeutics Corporation (BGEN) CAMP4 Therapeutics Corporation (GTBP) CAMP4 Therapeutics Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 13463J101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 62.75 Most Recent Split Date: (:1) Beta: 0.27 Market Capitalization: $276.74 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 65.64 EPS Growth vs. Year Ago Period: 64.52% vs. Previous Quarter: 31.25% Sales Growth vs. Year Ago Period: 18.84% vs. Previous Quarter: 37.48% ROE 06/30/26 - -252.79 03/31/26 - -194.74 12/31/25 - -162.49 ROA 06/30/26 - -85.65 03/31/26 - -95.64 12/31/25 - -101.06 Current Ratio 06/30/26 - 4.70 03/31/26 - 6.15 12/31/25 - 7.35 Quick Ratio 06/30/26 - 4.70 03/31/26 - 6.15 12/31/25 - 7.35 Operating Margin 06/30/26 - -2,047.30 03/31/26 - -2,193.72 12/31/25 - -2,298.54 Net Margin 06/30/26 - -2,543.74 03/31/26 - -2,193.72 12/31/25 - -2,298.54 Pre-Tax Margin 06/30/26 - -2,543.74 03/31/26 - -2,193.72 12/31/25 - -2,298.54 Book Value 06/30/26 - -0.01 03/31/26 - 0.60 12/31/25 - 1.02 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©